Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

Autor: H.J. Jansen, Helena M. de Wit, Cees J. Tack, Bastiaan E. de Galan, Wim J C de Grauw, Gerald Vervoort
Rok vydání: 2014
Předmět:
Zdroj: Diabetologia, 57, 1812-9
Diabetologia, 57, 9, pp. 1812-9
ISSN: 1432-0428
0012-186X
DOI: 10.1007/s00125-014-3302-0
Popis: Item does not contain fulltext AIMS/HYPOTHESIS: The best treatment strategy for a patient with type 2 diabetes who shows pronounced weight gain after the introduction of insulin treatment is unclear. We determined whether addition of a glucagon-like peptide-1 (GLP-1) analogue could reverse pronounced insulin-associated weight gain while maintaining glycaemic control, and compared this with the most practised strategy, continuation and intensification of standard insulin therapy. METHODS: In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient departments of one academic and one large non-academic teaching hospital in the Netherlands, adult patients with type 2 diabetes with >/= 4% weight gain during short-term (
Databáze: OpenAIRE